Novo Nordisk Business Model Canvas

Partnerships with public payers, private insurers and PBMs improve access and reimbursement, supporting formulary placement and patient affordability; by 2024 Novo Nordisk expanded payer deals covering millions of lives for GLP-1 therapies. Value‑based agreements tie outcomes to costs, shifting risk and lowering net spend for payers. Collaborative real‑world evidence programs (RWE) demonstrate effectiveness and adherence, aiding joint initiatives to broaden formulary inclusion and patient co‑pay assistance.

Academic alliances accelerate target validation and de-risk assets; CMOs and suppliers sustain scale across 10 global manufacturing sites; payer and PBM deals cover millions of lives supporting GLP-1 access; digital and patient group partnerships drive RWE and guideline adoption among >500M adults with diabetes.

HEOR modeling and budget-impact analyses underpin payer negotiations, quantifying cost offsets and real-world value to support pricing in 2024. Outcomes-based contracts tie reimbursement to measurable patient outcomes, sharing risk between payers and Novo Nordisk. HTA submissions are adapted to local bodies such as NICE, IQWiG and HAS to meet country-specific evidence demands. Affordability programs and patient-assistance schemes expand access across markets.

Discovery and >20 clinical programs in 2024 advanced diabetes, obesity and chronic‑disease candidates. Large‑scale peptide/biologic manufacturing with integrated sterile fill‑finish and device engineering sustained supply and adherence. HEOR, RWE and outcomes‑based contracts supported market access; pharmacovigilance and field medical teams (~69,000 employees) ensured uptake. 2024 revenue DKK 205.6 billion.

Scientific and clinical talent at Novo Nordisk—backed by a global workforce of over 60,000—drives endocrinology, metabolism and hematology innovation; cross-functional teams accelerate decisions. Robust clinical operations and regulatory functions support efficient approvals across a 300+ trial portfolio. Data science and bioinformatics bolster discovery and RWE, supported by roughly DKK 26bn R&D investment (2023).

Patents, trade secrets and FTO analyses protect GLP-1 and insulin franchises across 170+ markets, supporting launch sequencing. Global manufacturing, cold-chain logistics and DKK 22.8bn 2023 capex ensure supply scale; workforce ~60,000 and DKK 26bn R&D (2023) drive innovation. Regulatory, HEOR and clinician networks underpin access as the GLP-1 market topped USD 70bn (2024).

Robust global manufacturing networks underpin consistent availability, supporting Novo Nordisk’s scale that helped deliver DKK 176.9 billion in 2023 revenue. Stringent quality controls and pharmacovigilance reduce variability and recalls, maintaining high batch-release standards. Integrated cold-chain logistics and inventory planning minimize disruptions across key markets. Patients and providers can trust continuity of care.

Products cut disease burden: semaglutide 2.4 mg mean weight loss 14.9% vs 2.4% placebo (STEP1, 68 weeks) and SELECT showed 24% MACE reduction. Digital pens and services improve adherence amid WHO ~50% chronic‑disease nonadherence; 2024 saw semaglutide indication expansion. Global scale supports continuity (DKK 176.9 billion revenue 2023) and 2023–2024 HEOR models show favorable cost‑effectiveness.

Dedicated KAM teams negotiate access, rebates and outcomes contracts with payers, supporting over 100 payer agreements globally; data-sharing and analytics demonstrate real-world value of GLP-1 therapies through aggregated outcomes and cost-offset analyses. Joint pilots across multiple markets test innovative payment models, while regular quarterly reviews align on performance, utilization and reimbursement adjustments.

Medical liaisons, education and digital support drive clinician uptake; Novo Nordisk had >70,000 employees in 2024. Patient programs (onboarding, reminders, financial aid) raise persistence vs ~50% average adherence; global diabetes burden 537M (IDF 2021). KAMs manage 100+ payer agreements and outcomes pilots to prove value.

Hospital and public-system tenders secure bulk volume access for Novo Nordisk, supporting scale in hospitals and national programs; in 2024 the company reported about DKK 216 billion revenue, underpinning tender competitiveness. Strict compliance with procurement and GxP rules is critical to win contracts. Value dossiers emphasize patient outcomes and budget impact, and multi-year agreements (commonly 3–5 years) stabilize supply and pricing.

Field teams and CRM drive HCP initiation and capture insights; account-based tactics align with local formularies. Wholesale/specialty partners secure cold-chain across ~170 countries; 2024 revenue DKK 216 billion supports tender competitiveness. Digital tools (mySugr >3M users), e-prescribing and telehealth speed starts and adherence.

Patients with rare disorders include ≈400,000 people with haemophilia worldwide and growth hormone deficiency affecting roughly 1 in 3,500–10,000 children; both groups need specialized dosing, monitoring, and education. High-touch nurse-led services and home-infusion support are linked in studies to better adherence and fewer adverse events. Care is typically coordinated with hemophilia and endocrine centers of excellence to optimize outcomes.

Patients with diabetes and obesity seek effective, convenient GLP-1/insulin therapies with digital support; >537 million adults have diabetes (IDF 2021) and demand grows. Rare-disease and specialty endocrine/haemophilia patients need high-touch dosing, monitoring and home services. Providers, payers and PBMs (control ~80% US scripts in 2024) prioritize outcomes, cost-effectiveness and predictable supply.

Field forces, omnichannel campaigns and education drive adoption, with significant spend on sales and marketing to support global launches; in 2024 Novo Nordisk reported revenue above DKK 200 billion, underscoring scale-backed promotional investment. Medical engagement, clinical publications and congress activity require dedicated budgets and external funding. Launch costs peak around regulatory approvals and new indications, compressing cashflow. Ongoing compliance, certification and training add recurring overhead to SG&A.

R&D, trials and regulatory work drive fixed and per-patient costs (R&D DKK 25.9bn in 2024). Biologics manufacturing, devices and cold-chain raise unit COGS; manufacturing investments ~DKK 30bn in 2024. Sales, market access and support hubs create steady SG&A and access spend as global launches and HEOR/tenders increase market-specific costs.

Multi-year hospital and government contracts give Novo Nordisk predictable, recurring volumes and helped shore up supply planning amid the 2024 surge in GLP-1 demand.

These tenders often accept tighter unit margins in exchange for volume certainty, supporting capital allocation and manufacturing scale-up.

Performance clauses in contracts can trigger bonuses for delivery/efficacy or penalties for shortfalls, aligning incentives with payers.

Regulatory approvals and expanded indications in 2024 opened add-on volumes from institutional channels.

Prescription medicines (diabetes, obesity, haemophilia, growth) drove DKK 291.9 billion in 2024 sales, led by GLP-1 volume and US/China expansion. Devices and digital companions add recurring revenue and higher lifetime value. Licensing, milestones and royalties provide upfronts and ongoing income. Multi‑year tenders and performance contracts stabilize volumes and align payer incentives.